Drug
IB1001
IB1001 is a pharmaceutical drug with 6 clinical trials. Historical success rate of 60.0%.
Total Trials
6
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
60.0%
Based on 3 completed trials
Completion Rate
60%(3/5)
Active Trials
0(0%)
Results Posted
167%(5 trials)
Terminated
2(33%)
Phase Distribution
Ph phase_2
4
67%
Ph phase_3
2
33%
Phase Distribution
0
Early Stage
4
Mid Stage
2
Late Stage
Phase Distribution6 total trials
Phase 2Efficacy & side effects
4(66.7%)
Phase 3Large-scale testing
2(33.3%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
50.0%
3 of 6 finished
Non-Completion Rate
50.0%
3 ended early
Currently Active
0
trials recruiting
Total Trials
6
all time
Status Distribution
Completed(3)
Terminated(3)
Detailed Status
Completed3
Terminated2
Withdrawn1
Development Timeline
Analytics
Development Status
Total Trials
6
Active
0
Success Rate
60.0%
Most Advanced
Phase 3
Trials by Phase
Phase 24 (66.7%)
Phase 32 (33.3%)
Trials by Status
withdrawn117%
terminated233%
completed350%
Recent Activity
0 active trials
Showing 5 of 6
terminatedphase_2
N-Acetyl-L-Leucine for Ataxia-Telangiectasia (A-T)
NCT03759678
completedphase_2
N-Acetyl-L-Leucine for GM2 Gangliosidosis (Tay-Sachs and Sandhoff Disease)
NCT03759665
completedphase_2
N-Acetyl-L-Leucine for Niemann-Pick Disease, Type C (NPC)
NCT03759639
completedphase_2
Study of Recombinant Factor IX Product, IB1001, in Subjects With Hemophilia B
NCT00768287
terminatedphase_3
Study of Recombinant Factor IX Product, IB1001, in Previously Treated Pediatric Subjects With Hemophilia B
NCT01271868
Clinical Trials (6)
Showing 6 of 6 trials
NCT03759678Phase 2
N-Acetyl-L-Leucine for Ataxia-Telangiectasia (A-T)
NCT03759665Phase 2
N-Acetyl-L-Leucine for GM2 Gangliosidosis (Tay-Sachs and Sandhoff Disease)
NCT03759639Phase 2
N-Acetyl-L-Leucine for Niemann-Pick Disease, Type C (NPC)
NCT00768287Phase 2
Study of Recombinant Factor IX Product, IB1001, in Subjects With Hemophilia B
NCT01271868Phase 3
Study of Recombinant Factor IX Product, IB1001, in Previously Treated Pediatric Subjects With Hemophilia B
NCT02048111Phase 3
Study of Recombinant Factor IX Product, IB1001, in Previously Treated Subjects With Hemophilia B
All 6 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 6